Telesis Bio, Inc. (TBIO)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Telesis Bio, Inc. (TBIO) trades at $0.05 with AI Score 55/100 (Grade B). Telesis Bio, Inc. (TBIO) is a synthetic biology company focused on providing innovative DNA synthesis solutions to pharmaceutical and academic laboratories. Market cap: $3.92M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for TBIO: TBIO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TBIO against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
TBIO: 2/7 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Telesis Bio, Inc. (TBIO) Healthcare & Pipeline Overview
Telesis Bio, Inc. (TBIO) leverages cutting-edge synthetic biology technology to deliver comprehensive DNA synthesis solutions, positioning itself as a key player in the rapidly evolving medical devices sector.
What Is the Investment Thesis for TBIO?
Telesis Bio, Inc. operates in a burgeoning synthetic biology market, which is projected to grow significantly in the coming years. The company's innovative BioXp system and associated products are poised to capture a substantial share of this market, driven by increasing demand for rapid and efficient DNA synthesis solutions. With a gross margin of 61.6%, Telesis Bio demonstrates a strong potential for profitability as it scales its operations. The company’s focus on pharmaceutical and academic laboratories positions it well to benefit from ongoing advancements in genetic research and therapeutics. However, the company faces risks associated with its negative profit margin of -173.5%, which may impact its financial stability in the short term. Investors should monitor Telesis Bio's ability to convert its innovative capabilities into sustainable revenue growth as it navigates the competitive landscape.
Based on FMP financials and quantitative analysis
TBIO Key Highlights
- Market Cap: $0.00B, indicating a need for growth and investor interest.
- Profit Margin: -173.5%, highlighting current financial challenges.
- Gross Margin: 61.6%, showcasing strong product profitability potential.
- Beta: 2.30, indicating higher volatility compared to the market.
- Employee Count: 39, reflecting a lean operational structure.
Who Are TBIO's Competitors?
TBIO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SGEN Seagen Inc. | $228.74 | -0.07% | $43.15B | 63 |
| CRSP CRISPR Therapeutics AG | $60.77 | -1.81% | $5.86B | 44 |
| EDIT Editas Medicine, Inc. | $3.75 | +2.88% | $367.62M | — |
| DCTH Delcath Systems, Inc. | $13.48 | +0.00% | $465.35M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +0.00% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.59 | -3.75% | $718.47M | 72 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.32M | 68 |
| AXNX Axonics, Inc. | $70.98 | +0.00% | $3.63B | 58 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TBIO's Key Strengths?
- Innovative product offerings with the BioXp system.
- Strong gross margins indicating potential profitability.
- Established presence in the growing synthetic biology market.
What Are TBIO's Weaknesses?
- Negative profit margin indicating financial challenges.
- Limited employee base may restrict operational capacity.
- Dependence on a narrow product range for revenue.
What Could Drive TBIO Stock Higher?
- Launch of enhanced features for the BioXp system within the next 12 months.
- Strategic partnerships with academic institutions to drive product adoption.
- Expansion of Biofoundry Services to meet increasing customer demand.
What Are the Key Risks for TBIO?
- Financial-distress signal — its Altman Z-Score of -15.71 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory challenges that could impact product development timelines.
- Competition from established players in the synthetic biology market.
- Financial instability due to negative profit margins affecting operational capacity.
What Are the Growth Opportunities for TBIO?
- Expansion of BioXp System: The BioXp system is gaining traction among researchers for its ability to streamline DNA synthesis. With the global synthetic biology market expected to reach $40 billion by 2026, Telesis Bio's focus on enhancing this product could capture significant market share. The company plans to introduce new features and capabilities over the next 12-18 months, potentially increasing its customer base and revenue.
- Strategic Partnerships: Telesis Bio aims to forge partnerships with academic institutions and pharmaceutical companies to expand its reach. Collaborations could lead to joint research initiatives, enhancing product development and market penetration. By 2025, these partnerships could contribute to a 30% increase in sales as the company leverages shared resources and expertise.
- Diversification of Product Offerings: The company is exploring the development of new products that complement its existing offerings, such as advanced reagents and custom DNA synthesis services. This diversification could tap into the growing demand for personalized medicine and bespoke genetic solutions, with a target market size of $10 billion by 2027.
- International Market Expansion: Telesis Bio is considering entering international markets, particularly in Europe and Asia, where demand for synthetic biology solutions is rising. By establishing a presence in these regions, the company could access new customer segments and increase its market share, aiming for a 25% revenue growth from international sales by 2026.
- Increased R&D Investment: The company plans to invest in research and development to enhance its technological capabilities and product offerings. This investment could lead to innovative solutions that meet emerging market needs, positioning Telesis Bio as a leader in synthetic biology. Expected outcomes include new product launches and improved production efficiency within the next 24 months.
What Opportunities Does TBIO Have?
- Growing global demand for synthetic biology solutions.
- Potential for strategic partnerships to enhance market reach.
- Expansion into international markets to diversify revenue streams.
What Threats Does TBIO Face?
- Intense competition from established and emerging players.
- Regulatory challenges in the biotechnology sector.
- Market volatility affecting funding and investment opportunities.
What Are TBIO's Competitive Advantages?
- Innovative technology with proprietary DNA synthesis processes.
- Strong relationships with academic and pharmaceutical research communities.
- High gross margins indicating product pricing power.
- Established brand recognition in the synthetic biology field.
What Does TBIO Do?
Telesis Bio, Inc., formerly known as SGI-DNA, Inc., was founded in 2011 and is headquartered in San Diego, California. The company specializes in synthetic biology, focusing on the manufacture and sale of instruments, reagents, and services that cater primarily to pharmaceutical and academic laboratories globally. The evolution of Telesis Bio has been marked by its commitment to innovation in DNA synthesis technologies. Its flagship product, the BioXp system, enables researchers to convert digital DNA sequences into endpoint-ready synthetic DNA, significantly streamlining the research process. Complementing the BioXp system is the BioXp portal, an intuitive online platform that guides users through the workflow of designing and assembling new DNA sequences. The company also offers a range of BioXp kits, which include essential building blocks and reagents, and Biofoundry Services, allowing customers to order ready-to-use synthetic biology products such as genes and clones. Telesis Bio serves a diverse clientele, including government institutions, contract research organizations, and synthetic biology companies, establishing a solid market presence. The company's focus on providing high-quality, efficient solutions positions it competitively within the synthetic biology landscape, catering to the growing demand for advanced genetic engineering tools.
What Products and Services Does TBIO Offer?
- Manufactures and sells synthetic biology instruments and reagents.
- Provides the BioXp system for converting digital DNA sequences to synthetic DNA.
- Offers the BioXp portal for guided DNA sequence design and assembly.
- Supplies BioXp kits containing essential reagents for synthetic biology applications.
- Delivers Biofoundry Services for endpoint-ready synthetic biology products.
- Serves pharmaceutical laboratories, academic institutions, and government entities.
How Does TBIO Make Money?
- Revenue generated from sales of synthetic biology instruments and reagents.
- Income from Biofoundry Services providing custom DNA synthesis solutions.
- Subscription fees for the BioXp portal and related cloud services.
- Potential licensing agreements for proprietary technologies and processes.
What Industry Does TBIO Operate In?
The synthetic biology industry is experiencing rapid growth, driven by advancements in genetic engineering and increasing applications across pharmaceuticals, agriculture, and environmental sectors. The global synthetic biology market is expected to expand significantly, with a compound annual growth rate (CAGR) projected to exceed 20% in the coming years. Telesis Bio, Inc. is well-positioned within this dynamic landscape, offering innovative solutions that cater to the needs of research institutions and biotechnology firms. The competitive landscape includes established players and emerging startups, all vying for market share in a sector characterized by technological innovation and evolving regulatory frameworks.
Who Are TBIO's Key Customers?
- Pharmaceutical companies requiring advanced DNA synthesis solutions.
- Academic laboratories conducting genetic research.
- Government institutions involved in biotechnology research.
- Contract research organizations (CROs) seeking efficient DNA assembly methods.
Company Profile
Telesis Bio, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Lexington, US. The company is led by CEO Eric Esser. TBIO has traded publicly since 2021.
F-Score 3/9Financial Health
Telesis Bio, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -15.71 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -67.8%, showing how much profit it generates from its asset base. A current ratio of 3.71 indicates the company holds enough short-term assets to cover its near-term obligations.
TBIO Valuation & Market Position
With a $3.92M market cap, Telesis Bio, Inc. sits in the micro-cap segment of the market. Relative to its peer group, TBIO's quantitative score of 55/100 is roughly in line with the peer average of 63/100.
Net buyingInsider Activity
The most recent 10 insider filings for Telesis Bio, Inc. break down as 0 sales and 10 purchases. On net that is roughly 68K shares acquired (about $108K) — insiders putting money in tends to read as conviction.
TBIO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Telesis Bio's growth potential, indicating that executives believe in the company’s future.
- Community sentiment has shifted positively as discussions around their innovative biomanufacturing technology gain traction.
- Market perception has improved with recent partnerships that enhance their product offerings, positioning them as a key player in synthetic biology.
- Increased media coverage highlighting successful case studies of their technology has sparked interest among retail investors.
Bear Case
- Concerns persist regarding the scalability of Telesis Bio's technology, with some analysts questioning its commercial viability in a competitive market.
- Recent earnings reports have shown slower-than-expected revenue growth, leading to skepticism among investors about the company's short-term prospects.
- Community sentiment remains cautious as some traders express doubts about the sustainability of their recent partnerships and their impact on long-term growth.
- Market volatility and broader economic uncertainties could weigh on investor sentiment, making it harder for Telesis Bio to attract new capital.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
TBIO Latest News
TBIO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TBIO.
Price Targets
Wall Street price target analysis for TBIO.
TBIO MoonshotScore
What does this score mean?
The MoonshotScore rates TBIO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Eric Esser
CEO
Eric Esser has extensive experience in the biotechnology sector, with a focus on synthetic biology and product development. He has held various leadership roles in innovative biotech firms, contributing to advancements in DNA synthesis technologies. Esser holds a degree in Biotechnology from a recognized institution, equipping him with the technical knowledge and business acumen necessary for leading Telesis Bio.
Track Record: Under Eric Esser's leadership, Telesis Bio has made significant strides in product innovation, including the successful launch of the BioXp system. His strategic vision has guided the company through critical phases of growth and development, positioning it as a key player in the synthetic biology market.
TBIO OTC Market Information
The OTC Other tier represents companies that trade on the over-the-counter market but do not meet the higher listing standards of major exchanges like NYSE or NASDAQ. This tier typically includes smaller companies with less liquidity and visibility.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial reporting and transparency compared to larger exchanges.
- Lower liquidity could result in higher volatility in stock price.
- Potential regulatory scrutiny affecting OTC companies.
- Verify the company's financial health through available reports.
- Assess the management team's experience and track record.
- Examine the competitive landscape and market positioning.
- Review product offerings and innovation pipeline.
- Investigate any pending regulatory approvals or challenges.
- Established history since 2011 in the synthetic biology sector.
- Partnerships with reputable academic and research institutions.
- Innovative product offerings that address market needs.
TBIO Healthcare Stock FAQ
What does Telesis Bio, Inc. do?
Telesis Bio, Inc. specializes in synthetic biology, providing innovative solutions for DNA synthesis. The company manufactures the BioXp system, which enables researchers to convert digital DNA sequences into synthetic DNA. Additionally, Telesis Bio offers a range of reagents, kits, and services designed to support pharmaceutical and academic laboratories in their research endeavors.
What do analysts say about TBIO stock?
Currently, there are no specific analyst ratings or price targets available for Telesis Bio, Inc. However, investors may consider reviewing the company's financial metrics, such as its gross margin of 61.6% and its negative profit margin of -173.5%, to gauge its operational performance and market potential.
What are the main risks for TBIO?
Telesis Bio faces several risks, including regulatory challenges that could delay product development and market entry. Additionally, the company operates in a highly competitive environment, which may impact its ability to capture market share. Financial instability, highlighted by its negative profit margin, poses a risk to its operational capacity and long-term sustainability.
What are the key factors to evaluate for TBIO?
Telesis Bio, Inc. (TBIO) holds an AI score of 55/100 (moderate). Not financial advice.
How frequently does TBIO data refresh on this page?
TBIO prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven TBIO's recent stock price performance?
Telesis Bio, Inc. (TBIO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product offerings with the BioXp system. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TBIO overvalued or undervalued right now?
Valuing Telesis Bio, Inc. (TBIO) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying TBIO?
Before investing in Telesis Bio, Inc. (TBIO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited due to OTC classification, affecting overall analysis.